AM21-84: Identifying Current and Future Best Practices in Perinatal Patient Testing and Care
Oct 19, 2021 8:00pm ‐ Oct 19, 2021 9:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
The transfusion service plays a critical role in the management of perinatal patients. This interactive session will engage the audience and speakers in an active discussion on approaches for testing and management of this patient population. Topics presented are those identified as controversial or for which there is no unified approach and include:
- The timing and frequency of type and screens during pregnancy, and the need for type and screen with crossmatch at delivery.
- The indications to perform molecular tests i.e., maternal RHD genotyping to distinguish weak D from partial D and fetal RHD genotyping using cell-free DNA to make decisions regarding the need for monitoring and Rh immune globulin administration.
- Guidance about antibody critical titer thresholds and the appropriate management once critical titer is reached.
- Suggestions regarding which cord blood tests should and should not be performed to diagnose and assess future risk of hemolytic disease of the fetus and newborn.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Design a strategy for determining the frequency and interpretation of antibody titers and when referral to a high risk fetomaternal specialist is required.
- Identify which molecular tests are available and when they may be beneficial in the management of obstetric patients at risk for hemolytic disease of the fetus and newborn.
- Judge when and which tests performed on cord blood samples may benefit patient outcomes.
- Identify gaps where protocols and guidelines for the management of obstetrics patients are not available.
Moderator(s):
- Dr. Mark K. Fung, MD, PhD, Director of Clinical Laboratories, University of Vermont Medical Center
Speaker(s):
- Wen Lu, MD, Brigham and Women's Hospital
- Lani Lieberman, MD, University Health Network
Disclosures
- Wen Lu, MD:
Nothing to Disclose
- Lani Lieberman, MD:
Nothing to Disclose
- Mark Fung, MD, PhD:
Consultant: Cerus Corporation, Biocogniv; Honoraria: Grifols Corporation
AM21-85: A New Look at Two Familiar Topics: Platelet Transfusion Support for Immune Refractory Patients and the ABO COVID-19 Connection (AABB-ASHI Joint Symposium)
Oct 19, 2021 8:00pm ‐ Oct 19, 2021 9:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
In this session, our first presenter will discuss an unique algorithm for selecting compatible platelets for alloimmune refractory patients. The second presenter will review recent research on ABO antibodies and the differential susceptibility of ABO blood groups to COVID-19.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Describe the current findings regarding ABO and susceptibility to COVID-19 infection.
- Discuss how knowledge of the complexity of ABO antigens and antibodies may help explain differential susceptibility to COVID 19
- Compare the platelet donor selection method described in the presentation with the “HLA matching” method for selecting platelet donors for immune refractory patients
Moderator(s):
- Dr. Carol Pancoska, PhD, N/A-Independent Consultant
Speaker(s):
- Dr. Manish J. Gandhi, MD, Mayo Clinic
- Lori West, MD, DPhil, FRCPC, University of Alberta
Disclosures
- Manish Gandhi, MD:
Nothing to Disclose
- Carol Pancoska, PhD:
Nothing to Disclose
- Lori West, MD, DPhil, FRCPC:
Nothing to Disclose
AM21-86: AABB-ISCT Joint Working Group Project Updates
Oct 19, 2021 8:00pm ‐ Oct 19, 2021 9:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
In 2014, executive leadership at AABB and ISCT agreed to establish a joint working group (WG) for the purpose of identifying issues common to both organizations in the cellular therapy (CT) arena and exploring advocacy issues on which both organizations can collaborate. The WG has been involved in several projects since then. This session will provide updates on two of the current projects executed by two teams of experts recruited through the WG.
Project 1: Considerations for the Establishment of a CT Product Stability Program
The goals of the project are to:
- educate the community regarding considerations for CT stability programs
- create reference documents/communication materials to help with the design of a stability program for hematopoietic stem/progenitor cell products
Project 2: Establishment of a GTP interpretative tool that can assist with clarification of Human Cells, Tissues and Cellular-Based Products (HCT/Ps) regulations under 21 CFR 1271 and Section 361 of the PHS Act and/or the FD&C Act
The goals of this project are to:
- educate community regarding interpretation of GTP requirements and how best to prepare for FDA inspections of establishments that manufacture HCT/Ps
- create a tool providing section-by-section guidance specific to the needs of a CT laboratory to achieve regulatory compliance and preparation for unannounced FDA inspections
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Moderator & Speaker(s):
- Lizette Caballero, MLS(ASCP), Senior Laboratory Supervisor , Janssen Pharmaceutical Companies of Johnson & Johnson
Speaker(s):
- J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ), National Institutes of Health
- Nadim Mahmud, MD, PhD, University of Illinois College of Medicine
Disclosures
- J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ):
Nothing to Disclose
- Nadim Mahmud, MD, PhD:
Nothing to Disclose
AM21-91: Solve It! Scenarios in Cellular Therapy
Oct 19, 2021 11:30am ‐ Oct 19, 2021 1:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
We all face challenges in our daily work activities within Cellular Therapy: What is the best approach to manage storage space? How to deal with supply and reagents shortages? How to handle the growing number of clinical trials? How to be better prepared for the next disaster? Or how to adjust training and competency programs to accommodate the changing workforce?
The Solve It! Scenarios in Cellular Therapy session offers an interactive and constructive program for Cellular Therapy professionals to share challenges through case scenario presentations. This program permits attendees to select topics of particular interest, rotate through multiple scenario case presentations in small, informal groups, and develop problem solving strategies. Join us for lively interactions and networking with experts in the field of Cellular Therapy and fellow colleagues.
Closed captioning in English and Spanish is not available for this session.
Learning Objectives:- Discuss creative solutions to manage common technical, clinical, and administrative challenges using case scenario approach.
- Review regulatory requirements and accreditation standards while developing strategies to resolve mutual hurdles in daily practices.
- Assemble with cellular therapy colleagues and experts in the field in a congenial and informal atmosphere.
Moderator & Speaker(s):
- Ronit Slotky, PhD, MSc, Director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center
- Federico Rodriguez Quezada, SBB, MLS(ASCP), Collections and Processing Lab Facility Manager, UFHealth Shands
Speaker(s):
- Thomas Spitzer, MD, Massachusetts General Hospital & Harvard Medical School
- Indira Guleria, PhD Diplomate (ABHI), CABP(H), Beth Israel Deaconess Medical Center & Harvard Medical School
- Matt J. Wilgo, Cell Biology Scientist, New England Cryogenic Center
- Mike Halpenny, Canadian Blood Services
- Wanxing Cui, MedStar Georgetown University Hospital
Disclosures
- Ronit Slotky, PhD, MSc:
Nothing to Disclose
- Federico Rodriguez Quezada, SBB, MLS(ASCP):
Nothing to Disclose
- Indira Guleria, PhD Diplomate (ABHI), CABP(H):
Nothing to Disclose
- Wanxing Cui:
Nothing to Disclose
- Matt Wilgo:
Full-time/Part-time Employee New England Cryogenic Center
AM21-92: AABB Cellular Starting Material Forum
Oct 18, 2021 11:30am ‐ Oct 18, 2021 1:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
The AABB Cellular Starting Material (CSM) Forum connects cell collection organizations to the biotherapies ecosystem. CSM is used for a variety of novel biotherapies including cellular therapy, gene and cell therapy, and regenerative medicines. The CSM Forum explores standards development, industry, and regulatory perspectives as well as strengthening the capacity for cell collection organizations to meet current and future demand for qualification to collect CSM.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Describe the various forms of cellular starting material (CSM) in the biotherapies sector
- Recognize the connection between cell collection organizations as integral to the biotherapies ecosystem
- Explain current and future tools and resources available to AABB members
Moderator & Speaker(s):
- Linda S. Barnes, DrPH, MHA, RAC, AABB
Moderator(s):
- Eduardo Nunes, MPP, CAE, Vice President, Science and Practice, AABB
Speaker(s):
- Christopher Staub, Central California Blood Center
- Rawlinson Isaac, Rhode Island Blood Center
- Katie Zander, Standards Coordinating Body
- Amy DuRoss, Vineti
- Christopher Bocquet, Senior Director, Standards and Quality Initiatives, AABB
- Judy Arcidiacono, International Regulatory Expert, Standards Liaison, DHHS/FDA/CBER/CBER/OTAT
- Christine Alston-Roberts, Sr. Standards Manager, Parenteral Drug Association® (PDA)
- Jean Stanton, Director, Global Cell Collection, Janssen Pharmaceuticals
- Peter Holman, Vice President of Quality, ArsenalBio
- Tracey Hlucky, Sr. Manager, Quality Assurance, Kite Pharma
Disclosures
- Linda Barnes, DrPH, MHA, RAC:
Employee: X-Cell Systems
- Katie Zander:
Employee: Kite Pharma
- Christopher Bocquet:
Nothing to Disclose
- Judy Arcidiacono:
Nothing to Disclose
- Peter Holman:
Nothing to Disclose
- Tracey Hlucky:
Employee: Kite Pharma
- Jean Stanton:
Nothing to Disclose
- Eduardo Nunes, MPP, CAE:
Nothing to Disclose